Lipoprotein (a) Level Among Patients with Type 2 Diabetes Mellitus and Prediabetes in Comparison with Healthy Controls
DOI:
https://doi.org/10.25271/sjuoz.2023.11.1.996Keywords:
lipoprotein (a), diabetes mellitus type 2, prediabetesAbstract
Objective: Diabetes mellitus type 2 is a chronic endocrine condition defined as high blood glucose concentration and produced by either insulin resistance or relative lack of insulin, Prediabetes is a metabolic disorder defined by high blood glucose levels that are below the diagnostic threshold for diabetes mellitus. This study aimed to measure lipoprotein (a) levels in individuals with type 2 diabetes mellitus and prediabetic individuals.
Methods: A cross-sectional research was performed at Diabetes Unit at Azadi Teaching Hospital, Kurdistan region, Iraq. The study group consist of 235 participants, 85 type 2 diabetic patients, 60 prediabetic individuals and 90 individuals as control group.
Results: Mean levels of Lipoprotein (a) were higher in patients with type 2 diabetes mellitus (60.43±13.19 mg/dl) and prediabetic individuals (42.53±11.65 mg/dl) in comparison with healthy control (27.3±11.16 mg/dl). Moreover, there was higher prevalent rate of abnormal high lipoprotein (a) among type 2 diabetic patients (69 ,81.1%) and prediabetic individuals (10, 16.7%).
Conclusion: High mean level of lipoprotein (a) and high prevalence rate of abnormal high lipoprotein (a) were observed in type 2 diabetic patients and prediabetic individuals.
References
Al-Shaer, M. H., Elzaky, M. M., Farag, E. S. M., & Saad, M. O. M. (2021). In Type 2 Diabetes Mellitus Patients, the Atherogenic Index of Plasma as a Marker of Coronary Artery Diseases. Indian Journal of Clinical Cardiology, 2(4), 217-221.
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., ... & Welty, F. K. (2020). American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation, 141(19), e779-806.
Care, D. (2019). Care in Diabetes 2019. Diabetes Care, 42(1), S13-S28.
Bansal, N. (2015). Prediabetes diagnosis and treatment: A review. World journal of diabetes, 6(2), 296.
Bener, A., Zirie, M., Daghash, M. H., Al-Hamaq, A. O., Daradkeh, G., & Rikabi, A. (2007). Lipids, lipoprotein (a) profile and HbA1c among Arabian Type 2 diabetic patients. Biomedical research, 18(2), 97-102.
Bhowmik, B., Siddiquee, T., Mujumder, A., Afsana, F., Ahmed, T., Mdala, I. A., ... & Omsland, T. K. (2018). Serum lipid profile and its association with diabetes and prediabetes in a rural Bangladeshi population. International journal of environmental research and public health, 15(9), 1944.
Bo, M. S., Cheah, W. L., Lwin, S., Moe Nwe, T., Win, T. T., & Aung, M. (2018). Understanding the relationship between atherogenic index of plasma and cardiovascular disease risk factors among staff of a University in Malaysia. Journal of Nutrition and Metabolism, 2018.
Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., Bonadonna, R. C., & Muggeo, M. (2003). Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes care, 26(4), 1251-1257.
Boronat, M., Saavedra, P., Pérez-Martín, N., López-Madrazo, M. J., Rodríguez-Pérez, C., & Nóvoa, F. J. (2012). High levels of lipoprotein (a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovascular diabetology, 11(1), 1-6.
Cândido, A. P. C., Ferreira, S., Lima, A. A., de Carvalho Nicolato, R. L., de Freitas, S. N., Brandão, P., ... & Machado-Coelho, G. L. L. (2007). Lipoprotein (a) as a risk factor associated with ischemic heart disease: Ouro Preto Study. Atherosclerosis, 191(2), 454-459.
Cerf, M. E. (2013). Beta cell dysfunction and insulin resistance. Frontiers in endocrinology, 4, 37.
Chamberlain, J. J., Rhinehart, A. S., Shaefer Jr, C. F., & Neuman, A. (2016). Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Annals of internal medicine, 164(8), 542-552.
Daghash, M. H., Bener, A., Zirie, M., Dabdoob, W., Al-Hamaq, A. O., & Al-Arabi, Z. A. (2007). Lipoprotein profile in Arabian type 2 diabetic patients. Relationship to coronary artery diseases. International journal of cardiology, 121(1), 91-92.
Dai, W., Long, J., Cheng, Y., Chen, Y., & Zhao, S. (2018). Elevated plasma lipoprotein (a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. Scientific reports, 8(1), 1-9.
Daniel, M. J. (2011). Lipid management in patients with type 2 diabetes. American health & drug benefits, 4(5), 312.
Ding, L., Song, A., Dai, M., Xu, M., Sun, W., Xu, B., ... & Ning, G. (2015). Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population [S]. Journal of lipid research, 56(4), 920-926.
Draznin, B., Aroda, V. R., Bakris, G., Benson, G., Brown, F. M., Freeman, R., ... & Kosiborod, M. (2022). 16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45(Supplement_1), S244-S253.
Fan, W. (2017). Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular endocrinology, 6(1), 8.
Gao, L., Zhang, Y., Wang, X., & Dong, H. (2021). Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study. BMC endocrine disorders, 21(1), 1-11.
Habib, S. S. (2013). Serum lipoprotein (a) and high sensitivity C reactive protein levels in Saudi patients with type 2 diabetes mellitus and their relationship with glycemic control. Turkish Journal of Medical Sciences, 43(2), 333-338.
Haghighatdoost, F., Amini, M., Feizi, A., & Iraj, B. (2017). Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: Results from a population based cohort study. World journal of diabetes, 8(7), 365.
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020). Triglycerides and ASCVD risk reduction: recent insights and future directions. Current Atherosclerosis Reports, 22(7), 1-10.
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., ... & Brown, W. V. (2015). National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. Journal of clinical lipidology, 9(2), 129-169.
Jin, J. L., Cao, Y. X., Zhang, H. W., Sun, D., Hua, Q., Li, Y. F., ... & Li, J. J. (2019). Lipoprotein (a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care, 42(7), 1312-1318.
Joseph, J., Ganjifrockwala, F., & George, G. (2016). Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients. Oxidative Medicine and Cellular Longevity, 2016.
Karmakar, P. H. (2020). Association of Serum Lipoprotein(a) with Fasting Lipid Profile in Type 2 Diabetic Patients. Eastern Medical College Journal, 5, 18-22.
Klesareva, E. A., Afanas’eva, O. I., Donskikh, V. V., Adamova, I. Y., & Pokrovskii, S. N. (2016). Characteristics of lipoprotein (a)-containing circulating immune complexes as markers of coronary heart disease. Bulletin of experimental biology and medicine, 162(2), 231-236.
Lamina, C., & Ward, N. C. (2022). Lipoprotein (a) and diabetes mellitus. Atherosclerosis, 349, 63-71.
Li, C. L., Chen, S. Y., Lan, C., Pan, W. H., Chou, H. C., Bai, Y. B., ... & Lai, J. S. (2011). The effects of physical activity, body mass index (BMI) and waist circumference (WC) on glucose intolerance in older people: a nationwide study from Taiwan. Archives of Gerontology and Geriatrics, 52(1), 54-59.
Li, Y. W., Kao, T. W., Chang, P. K., Chen, W. L., & Wu, L. W. (2021). Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study. Scientific reports, 11(1), 1-8.
Lotfy, M., Adeghate, J., Kalasz, H., Singh, J., & Adeghate, E. (2017). Chronic complications of diabetes mellitus: a mini review. Current diabetes reviews, 13(1), 3-10.
Ma, X., Sun, Y., Cheng, Y., Shen, H., Gao, F., Qi, J., ... & Zhou, Y. (2020). Prognostic impact of the atherogenic index of plasma in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention. Lipids in Health and Disease, 19(1), 1-13.
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., ... & Wiklund, O. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal, 41(1), 111-188.
Málek, F., Dvořák, J., Skalníková, V., Mates, M., Kmoníček, P., Vávrová, Z., & Neužil, P. (2015). Correlation of lipoprotein (a) with the extent of coronary artery disease in patients with established coronary atherosclerosis: gender differences. European Journal of Preventive Cardiology, 22(5), 603-605.
Maranhão, R. C., Carvalho, P. O., Strunz, C. C., & Pileggi, F. (2014). Lipoprotein (a): structure, pathophysiology and clinical implications. Arquivos brasileiros de cardiologia, 103, 76-84.
Mirhosseini, N., Vatanparast, H., Mazidi, M., & Kimball, S. M. (2018). Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: a meta-analysis. Journal of the Endocrine Society, 2(7), 687-709.
Mohieldein, A. H., Abdalla, K. E., & Hasan, M. (2014). Lipoprotein (a) and atherogenic indices in Sudanese patients with type 2 diabetes. International journal of health sciences, 8(3), 237.
Nuttall, F. Q. (2015). Body mass index: obesity, BMI, and health: a critical review. Nutrition today, 50(3), 117.
Ogbera, A. O., & Azenabor, A. O. (2010). Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM. Diabetology & metabolic syndrome, 2(1), 1-5.
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018). Association between insulin resistance and the development of cardiovascular disease. Cardiovascular diabetology, 17(1), 1-14.
Ozder, A. (2014). Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids in health and disease, 13(1), 1-6.
Peela, J. R., Latiwesh, O. B., Elshaari, F., Hussain, A., Tabrez, E., Viglianco, E., ... & Rawal, A. K. (2018). Investigating the atherogenic risk of lipoprotein (a) in type 2 diabetic patients. Cureus, 10(7).
Ponti, F., Santoro, A., Mercatelli, D., Gasperini, C., Conte, M., Martucci, M., ... & Bazzocchi, A. (2020). Aging and imaging assessment of body composition: from fat to facts. Frontiers in endocrinology, 10, 861.
Premkumar, K. S. (2006). A Study on Lipoprotein (A) in Health and Type-2 Diabetes Mellitus (Doctoral dissertation, Madras Medical College, Chennai).
Ren, X., Zhang, Z., & Yan, Z. (2021). Association between lipoprotein (a) and diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis. Frontiers in Endocrinology, 12, 633529.
Riches, K., & Porter, K. E. (2012). Lipoprotein (a): cellular effects and molecular mechanisms. Cholesterol, 2012.
Saeed, A., Sun, W., Agarwala, A., Virani, S. S., Nambi, V., Coresh, J., ... & Hoogeveen, R. C. (2019). Lipoprotein (a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis, 282, 52-56.
Shah, N. P., Pajidipati, N. J., McGarrah, R. W., Navar, A. M., Vemulapalli, S., Blazing, M. A., ... & Patel, M. R. (2020). Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations. The American journal of cardiology, 126, 94-102.
Stacey, R. B., Leaverton, P. E., Schocken, D. D., Peregoy, J. A., & Bertoni, A. G. (2015). Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis. American heart journal, 170(5), 923-928.
Stepanek, L., Horakova, D., Nakladalova, M., Cibickova, L., Karasek, D., & Zadrazil, J. (2018). Significance of prediabetes as a nosological entity. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 162(4).
Su, W., Cao, R., He, Y. C., Guan, Y. F., & Ruan, X. Z. (2017). Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease. kidney diseases, 3(4), 171-180.
Sudesna, C., Khunti, K., & Davies, M. J. (2017). Type 2 diabetes. The Lancet, 389(10085), 2239-2251.
Vaverková, H., Karásek, D., Halenka, M., Cibickova, L., & Kubickova, V. (2017). Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects. Physiological Research, 66, S113.
Viigimaa, M., Sachinidis, A., Toumpourleka, M., Koutsampasopoulos, K., Alliksoo, S., & Titma, T. (2020). Macrovascular complications of type 2 diabetes mellitus. Current vascular pharmacology, 18(2), 110-116.
Weitzman, S. (2016). The link between diabetes and cardiovascular disease: The epidemiological perspective. The Israel Medical Association journal: IMAJ, 18(12), 709-711.
Zhang, Y., Jin, J. L., Cao, Y. X., Zhang, H. W., Guo, Y. L., Wu, N. Q., ... & Li, J. J. (2020). Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovascular diabetology, 19(1), 1-10.
Zheng, S., Han, T., Xu, H., Zhou, H., Ren, X., Wu, P., ... & Hu, Y. (2017). Associations of apolipoprotein B/apolipoprotein AI ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults. BMJ open, 7(1), e014038.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Barhav Issa Abdullah, Sherwan Ferman Salih
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work, with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online.
